Article
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.
Nature communications - 31 Aug 2016
Jung Joonil, Lee Joon Sang, Dickson Mark A, Schwartz Gary K, Le Cesne Axel, Varga Andrea, Bahleda Rastilav, Wagner Andrew J, Choy Edwin, de Jonge Maja J, Light Madelyn, Rowley Steve, Macé Sandrine, Watters James
Abstract excerpt
In tumours that harbour wild-type p53, p53 protein function is frequently disabled by the mouse double minute 2 protein (MDM2, or HDM2 in humans). Multiple HDM2 antagonists are currently in clinical development. Preclinical data indicate that TP53 mutations are a possible mechanism of acquired resistance to HDM2 inhibition; however, this resistance mechanism has not been reported in patients. Utilizing liquid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.